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Background
Leptospirosis is a zoonotic disease caused by pathogenic
bacteria belonging to the genus Leptospira and more than
1 million cases occur worldwide annually. Several mam-
mals may carry the agent, and rats are the most important
source of human infection in urban settings. The Leptos-
pira surface proteins have an important role during
pathogen infection and some of these allow the differentia-
tion between pathogenic and non-pathogenic species.
Among these, the LigA and LigB adhesins are surface
localized proteins that interact with the proteins of extra-
cellular matrix and fibrinogen. Therefore, antibodies
against these targets are useful tools in immunodiagnostic
assays.
Methods
The goal of this study was to generated monoclonal anti-
bodies (mAbs) against a truncated fragment of approxi-
mately 54 kDa, named rLigBrep, that comprise a identical
portion of LigA and LigB (domains 2-7). For the mAbs
production, two BALB/c mice were inoculated via intra-
peritoneal with 150 µg of rLigBrep on days 0, 14, 21 and
28. Freund’s complete adjuvant was used in the first dose
and incomplete in the subsequent ones. Four days before
cellular fusion the mouse with the highest titer in indirect
ELISA (1:64000) was boosted with 20 µg of protein intra-
venously. Splenic lymphocytes were fused to murine Sp2/
O-Ag14 myeloma cells in the presence of PEG 1450.
Fused cells were cultivated in Dulbecco’s modified Eagle
medium containing 20% fetal calf serum and supplemen-
ted with hypoxanthine, aminopterin and thymidine
(HAT). Hybridomas growing in HAT medium were
screened by indirect ELISA and those positive for rLigBrep
were cloned twice by limiting dilution, expanded and
stored in liquid nitrogen.
Results and conclusion
Two hibridomas (ID-Ra and ID-Rg) were obtained and
used for ascites production. An indirect ELISA was per-
formed to verify antibodies presence in ascites fluid. The
mAbs presented high titres against rLigBrep (ID-Ra
51,200 and ID-Rg 128,000, respectively). In conclusion,
the mAbs produced in this study can be useful tools in
immunodiagnostic assays for leptospirosis.
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